Precision BioSciences (DTIL) Projected to Post Earnings on Thursday

Key Points

• Precision BioSciences is set to announce its Q2 2025 earnings on Thursday, August 7th, with analysts predicting a loss of ($0.09) per share and revenue of $6.27 million.
• In the last earnings report, the company reported a significant miss with an EPS of ($2.21) and revenue of only $0.03 million compared to expectations of ($0.43) and $5.00 million, respectively.
• CFO John Alexander Kelly recently sold 14,827 shares of his stock, marking a 16.79% decrease in his position, with current insider ownership at 4.5% of the company's stock.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $6.27 million for the quarter.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($2.21) EPS for the quarter, missing the consensus estimate of ($0.43) by ($1.78). Precision BioSciences had a negative net margin of 42.99% and a negative return on equity of 69.26%. The firm had revenue of $0.03 million for the quarter, compared to analysts' expectations of $5.00 million. On average, analysts expect Precision BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Precision BioSciences Trading Down 2.7%

Precision BioSciences stock traded down $0.13 during trading on Friday, hitting $4.62. The company had a trading volume of 61,917 shares, compared to its average volume of 216,125. Precision BioSciences has a 1-year low of $3.61 and a 1-year high of $11.09. The company has a current ratio of 6.62, a quick ratio of 6.62 and a debt-to-equity ratio of 0.45. The company's 50 day simple moving average is $4.75 and its 200-day simple moving average is $4.94. The stock has a market cap of $51.24 million, a price-to-earnings ratio of -2.30 and a beta of 1.52.

Insider Activity at Precision BioSciences

In related news, CFO John Alexander Kelly sold 14,827 shares of the company's stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $4.26, for a total transaction of $63,163.02. Following the transaction, the chief financial officer owned 73,485 shares of the company's stock, valued at approximately $313,046.10. This represents a 16.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 4.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $60.00 target price on shares of Precision BioSciences in a report on Wednesday, May 21st.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.